Status:

ACTIVE_NOT_RECRUITING

Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)

Lead Sponsor:

NS Pharma, Inc.

Collaborating Sponsors:

Nippon Shinyaku Co., Ltd.

Conditions:

Duchenne Muscular Dystrophy

Eligibility:

MALE

Phase:

PHASE3

Brief Summary

This is a Phase 3, multi-center, open-label extension study in ambulant boys with DMD who have completed the 48-week treatment period of either viltolarsen or placebo in Study NS-065/NCNP-01-301.

Detailed Description

This Phase 3 study is a multi-center, open-label extension study in ambulant boys with DMD who have completed the 48-week treatment period of either viltolarsen or placebo in Study NS-065/NCNP-01-301....

Eligibility Criteria

Inclusion

  • Patient has completed the NS-065/NCNP-01-301 study;
  • Patient's parent(s) or legal guardian(s) has (have) provided written informed consent and Health Insurance Portability and Accountability Act authorization, where applicable, prior to any study-related procedures; patients will be asked to give written or verbal assent according to local requirements;
  • Patient and parent(s)/guardian(s) are willing and able to comply with scheduled visits, investigational product (IP) administration plan, and study procedures.

Exclusion

  • Patient had an adverse event in Study NS-065/NCNP-01-301 that, in the opinion of the investigator and/or the sponsor, precludes safe use of viltolarsen for the patient in this study;
  • Patient had a treatment which was made for the purpose of dystrophin or dystrophin-related protein induction after completion of Study NS-065/NCNP-01-301;
  • Patient took any other investigational drug(s) during or after completion of Study NS-065/NCNP-01-301;
  • Patient is judged by the investigator and/or the sponsor not to be appropriate to participate in the extension study for any reason.

Key Trial Info

Start Date :

April 13 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2025

Estimated Enrollment :

74 Patients enrolled

Trial Details

Trial ID

NCT04768062

Start Date

April 13 2021

End Date

November 1 2025

Last Update

February 14 2024

Active Locations (31)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 8 (31 locations)

1

Queensland Children's Hospital

Brisbane, Australia

2

The Childrens Hospital at Westmead

Westmead, Australia

3

CHU de Quebec Research Centre

Québec, Canada

4

Hospital de Niños Roberto del Rio

Santiago, Chile